PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (25 reviews)

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

25 publications

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 25 publications

Nat Commun, 2020, 11(1):3200

PubMed: 32581239 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):153

PubMed: 32843616 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001183R

PubMed: 32686868 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Clin Exp Allergy, 2017, 47(4):488-498

PubMed: 28000949 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52239-52254

PubMed: 27409169 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Immunol, 2015, 195(6):2529-39

PubMed: 26276876 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )
Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP6TWM2OD1yLkiyNFI1KM7:TR?=	MnnHV2FPT0WU
UACC-893	M{LxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\MTWM2OD13LkG5PFg3KM7:TR?=	MnfXV2FPT0WU
A427	NIXHeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO1Z5M4UUN3ME21MlczPTZ5IN88US=>	NUPzOHRkW0GQR1XS
OCUB-M	NUWxUHl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTZwNk[xNFIh\|ryP	NXPKRYpkW0GQR1XS
SW684	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\3TWM2OD15LkWyNlY5KM7:TR?=	NHTYW4FUSU6JRWK=
SK-LMS-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe5boE5UUN3ME25MlAyOzB{IN88US=>	MYXTRW5ITVJ?
CP50-MEL-B	NVf5flBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnMTWM2OD17LkOwOFE6KM7:TR?=	M1\Pe3NCVkeHUh?=
NCI-H1651	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nse2lEPTB;MUCuNFI4PiEQvF2=	M1zjTHNCVkeHUh?=
ABC-1	M4G0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTBTWM2OD1zMD6xNFM4KM7:TR?=	Mmn5V2FPT0WU
OE19	NWnyVVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFyLkG3N\|Mh\|ryP	NFnJTJFUSU6JRWK=
DSH1	NFrOUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFyLki4O\|kh\|ryP	MmK1V2FPT0WU
SW13	NVL5NIVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDMem1tUUN3ME2xNU46OzF7IN88US=>	MUfTRW5ITVJ?
MDA-MB-453	M1\J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmH4TWM2OD1zMj6xOlA{KM7:TR?=	NXnEUHF3W0GQR1XS
647-V	M4HqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkmyTWM2OD1zMj6zOVgzKM7:TR?=	MVPTRW5ITVJ?
NCI-H2342	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\hTJhHUUN3ME2xNk4{QTl3IN88US=>	M{\Jb3NCVkeHUh?=
LB2241-RCC	Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPBeVFKSzVyPUGyMlU4PzlizszN	M37LcXNCVkeHUh?=
UACC-257	NUH2fWhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XxU2lEPTB;MUOuOFQ2OyEQvF2=	NH\3[lRUSU6JRWK=
NCI-H661	NUn0WIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLBVmNKSzVyPUGzMlY1PDlizszN	MUjTRW5ITVJ?
FADU	NUHWXZVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF\|Lk[5PVIh\|ryP	MnnwV2FPT0WU
A2780	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jFSmlEPTB;MUOuPFA1OSEQvF2=	NVW4TVN{W0GQR1XS
NCI-H1793	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[1RYxDUUN3ME2xOE41ODh3IN88US=>	M{js[XNCVkeHUh?=
TE-8	NHSweHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rsNmlEPTB;MUWuN\|Q3PSEQvF2=	NW\VVXU1W0GQR1XS
HGC-27	NUXHN\|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3G5OGlEPTB;MU[uNVY1PCEQvF2=	NUXPeI9ZW0GQR1XS
MMAC-SF	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTF5LkO3Nlch\|ryP	NVjLN3RVW0GQR1XS
Calu-6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTF6LkG1NVMh\|ryP	NFvvdZNUSU6JRWK=
HUTU-80	NWOybZhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTF6LkO5OVkh\|ryP	MUjTRW5ITVJ?
SAS	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzqVHBKSzVyPUG4MlY1PTVizszN	NYrMN4pNW0GQR1XS
IST-MES1	M4\x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj2bWlKSzVyPUG4MlY2ODhizszN	NE\ZR3VUSU6JRWK=
C3A	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTF6Lke5NVkh\|ryP	M1jRTHNCVkeHUh?=
ES3	NFTSdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXubFl5UUN3ME2xPE45OzZ2IN88US=>	MVLTRW5ITVJ?
HSC-2	NHS2coRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfNUoFKSzVyPUG5MlY2PDFizszN	MkTaV2FPT0WU
T47D	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHMbYpKSzVyPUKwMlE1QDVizszN	Mm\XV2FPT0WU
EW-7	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTJyLki1PFgh\|ryP	MmTuV2FPT0WU
LN-405	MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7tVHRTUUN3ME2yNE45QTZ3IN88US=>	M{HDZnNCVkeHUh?=
U031	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLuTWM2OD1{MT60PFAzKM7:TR?=	M37yR3NCVkeHUh?=
A549	NI\FVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HFRmlEPTB;MkGuPFQ6OSEQvF2=	MlzvV2FPT0WU
RMG-I	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1KySWlEPTB;MkKuNlY3QCEQvF2=	NIS4NotUSU6JRWK=
BT-474	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvmNow4UUN3ME2yNk43PTVzIN88US=>	M3X2c3NCVkeHUh?=
NB69	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHJSmdlUUN3ME2yN{4yPTJizszN	Mn3qV2FPT0WU
NB7	M{jVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vV[GlEPTB;MkSuNVg5KM7:TR?=	NUXIcmRyW0GQR1XS
HCC1569	NXztT3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vMO2lEPTB;MkSuOlEzPSEQvF2=	NY\HT\|lWW0GQR1XS
MEL-JUSO	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJ2Lk[5NFgh\|ryP	MVfTRW5ITVJ?
MDA-MB-175-VII	NX32XYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vTbWlEPTB;MkWuNlUyPyEQvF2=	NGnMbItUSU6JRWK=
HCC1419	NVP5W\|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfRTWM2OD1{NT62NFA{KM7:TR?=	NX;Je5RmW0GQR1XS
Ca9-22	MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPwTWM2OD1{NT62OFMzKM7:TR?=	M1P1cHNCVkeHUh?=
KGN	NEHtflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G1VGlEPTB;MkWuO\|U1PyEQvF2=	MkLZV2FPT0WU
LB373-MEL-D	M2HFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\ZcYhZUUN3ME2yOk4yQTN6IN88US=>	NUHXOplpW0GQR1XS
NCI-H1755	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfjTWM2OD1{Nj64PFQyKM7:TR?=	NIn1PHZUSU6JRWK=
D-423MG	MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj1[2FKSzVyPUK3MlA4OTVizszN	NFvuWpVUSU6JRWK=
DK-MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHOXnRKSzVyPUK4Mlc5PDZizszN	M2PSenNCVkeHUh?=
NCI-H1623	NX:1bIE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ6LkizOFIh\|ryP	NYe2ZoM1W0GQR1XS
KU-19-19	NYKxbllwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXHb\|ZKSzVyPUK4Mlk6PSEQvF2=	NF7Qd3ZUSU6JRWK=
C-33-A	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETINFBKSzVyPUK5MlIyQThizszN	MVnTRW5ITVJ?
SCC-4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3MTWM2OD1\|MD6zN\|U1KM7:TR?=	NUD6S4NCW0GQR1XS
MG-63	NF7FdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEeyeY5KSzVyPUOwMlU6QTRizszN	NHHmeHVUSU6JRWK=
LNCaP-Clone-FGC	NVTqbGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1X5dmlEPTB;M{GuOFkzOSEQvF2=	NXzQSmd1W0GQR1XS
CAPAN-1	NXn5ToZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr6TZBwUUN3ME2zNU42Ojh4IN88US=>	NXjNVZRiW0GQR1XS
GI-ME-N	M2HZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7iTWM2OD1\|MT61N\|U{KM7:TR?=	MVvTRW5ITVJ?
RERF-LC-MS	NI\v[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTN{Lk[3OFch\|ryP	NWPZbZBPW0GQR1XS
KLE	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzJe2k2UUN3ME2zN{41OzN2IN88US=>	NV3kO2JPW0GQR1XS
KNS-81-FD	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITkbIFKSzVyPUOzMlUxODhizszN	NF[5PXRUSU6JRWK=
DOK	NEDHZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;STWM2OD1\|ND62OlEzKM7:TR?=	MlfKV2FPT0WU
ACHN	M1[4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzpWIZKSzVyPUO1MlE2QDhizszN	MmLPV2FPT0WU
KYSE-520	M3HGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3CWIJoUUN3ME2zOU4zOzZzIN88US=>	NXvpVmh[W0GQR1XS
SBC-5	NUTTO4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHT1T4FKSzVyPUO1MlUyOTZizszN	NFTse\|RUSU6JRWK=
NCI-H28	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTN3Lk[2PVUh\|ryP	Ml7uV2FPT0WU
ES7	M{fy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDtSHRKSzVyPUO2MlIzPDlizszN	M1vkdnNCVkeHUh?=
A172	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXnTWM2OD1\|Nj60NVg4KM7:TR?=	MVjTRW5ITVJ?
UM-UC-3	NWPRNVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[zS2p4UUN3ME2zO{45PzR4IN88US=>	MWPTRW5ITVJ?
LXF-289	M3HHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3qT5JvUUN3ME2zPE4xODR5IN88US=>	NE\aXXZUSU6JRWK=
KP-4	M3[4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXewcFVPUUN3ME2zPE41PzN7IN88US=>	MnzZV2FPT0WU
TE-1	NGXZRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTQZZlIUUN3ME2zPU43PTh7IN88US=>	MVjTRW5ITVJ?
G-402	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjZTWM2OD12MD6wOlEh\|ryP	MnfqV2FPT0WU
786-0	NUK1S3JOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTRyLkmwPVYh\|ryP	MlfWV2FPT0WU
K5	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LxSmlEPTB;NEGuN\|Y5PiEQvF2=	NIjaTGhUSU6JRWK=
SK-N-DZ	NWLVNHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXuTWM2OD12MT6zPFI{KM7:TR?=	MUHTRW5ITVJ?
OVCAR-4	M{GxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvCSXRKSzVyPUSxMlc2PjhizszN	NVPsO2o2W0GQR1XS
T84	Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELufWdKSzVyPUSyMlEzPjNizszN	NFm2VphUSU6JRWK=
GCIY	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rRPGlEPTB;NEOuNFgxOyEQvF2=	NHO5R5JUSU6JRWK=
BB49-HNC	NHnQ[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWSxe4U2UUN3ME20N{4{OzR6IN88US=>	NUfydGY{W0GQR1XS
SNU-C2B	M4jqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vhNmlEPTB;NEOuOlQ{PiEQvF2=	MXrTRW5ITVJ?
TE-6	NGW0NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTWXnNXUUN3ME20N{45QDl2IN88US=>	NV3xbnpMW0GQR1XS
23132-87	NX[zU2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFftXYxKSzVyPUS0MlI6PzhizszN	MX\TRW5ITVJ?
DMS-53	M13LV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXu1R2VkUUN3ME20OE4{Ozh2IN88US=>	MknQV2FPT0WU
ONS-76	NVPYclQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS5UGhqUUN3ME20OE44PjZzIN88US=>	M3fqSXNCVkeHUh?=
DMS-273	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTR2Lkm0N{DPxE1?	NIDye4xUSU6JRWK=
COLO-824	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXy2V5JRUUN3ME20OU45Pzd3IN88US=>	NHnmco5USU6JRWK=
DMS-114	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7BUGlKSzVyPUS1Mlg6OjdizszN	M1fQPXNCVkeHUh?=
YKG-1	NHrWUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\1UmlEPTB;NE[uNFM2PSEQvF2=	NX25S\|NVW0GQR1XS
RH-18	M3TmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTR4LkO3N\|Mh\|ryP	Mo\4V2FPT0WU
NCI-H1355	NIr6UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVn0WmRCUUN3ME20Ok43OThizszN	M1rofXNCVkeHUh?=
NCI-H2170	NYnNVmc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;nXo0zUUN3ME20O{44PTh2IN88US=>	MoLsV2FPT0WU
OC-314	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlz6TWM2OD12Nz64OFc5KM7:TR?=	NIHjbWVUSU6JRWK=
NCI-H2030	M3XwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zmNGlEPTB;NEeuPFkxPiEQvF2=	MXHTRW5ITVJ?
22RV1	M{LDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTR5LkmwNVUh\|ryP	NYK5VYtZW0GQR1XS
G-401	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7sUHZKSzVyPUS4MlQ1OTVizszN	NUTnOlNOW0GQR1XS
YAPC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTR7LkiwO\|Mh\|ryP	M3PvWXNCVkeHUh?=
SW1573	NI\NN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTVyLkK0N\|Uh\|ryP	MlTBV2FPT0WU
COLO-792	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULU[\|hOUUN3ME21NE43OjN5IN88US=>	Moj3V2FPT0WU
KNS-62	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HL[WlEPTB;NUCuO\|UxQCEQvF2=	MWfTRW5ITVJ?
NB5	NFHjbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\0TWM2OD13MT60OVA6KM7:TR?=	M3fybnNCVkeHUh?=
CP66-MEL	NIjqSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i4TmlEPTB;NUGuOlQxQCEQvF2=	MXTTRW5ITVJ?
CaR-1	NIjYUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTV{LkC2NFYh\|ryP	M1TITHNCVkeHUh?=
CAL-54	M1PsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zGTGlEPTB;NUKuNVExOiEQvF2=	MkjpV2FPT0WU
8305C	NXG0W\|JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\qTIJlUUN3ME21Nk4{OTVizszN	M2LlenNCVkeHUh?=
Calu-3	NX;BXGdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjNcHFVUUN3ME21Nk4{PzN\|IN88US=>	M4LUcXNCVkeHUh?=
AU565	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\MWYlKSzVyPUWyMlU2ODlizszN	MWPTRW5ITVJ?
CW-2	NH3sT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\VTWM2OD13Mj64OlU1KM7:TR?=	MXXTRW5ITVJ?
BEN	NGPlWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf2TWM2OD13Mz63PFYzKM7:TR?=	MojSV2FPT0WU
NCI-H1975	NGHGbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[1UVR7UUN3ME21N{45QTZ4IN88US=>	Mmr3V2FPT0WU
HCT-116	NFzMPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTV2LkCzNlch\|ryP	NXG1W4hNW0GQR1XS
SH-4	NUXUfW42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7iTWM2OD13ND6xN\|gh\|ryP	MWLTRW5ITVJ?
NCI-H1693	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrwOVVKSzVyPUW0MlIyODNizszN	MlW4V2FPT0WU
BPH-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rMOGlEPTB;NUWuNlg6OiEQvF2=	MVHTRW5ITVJ?
CAMA-1	NWewU\|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[4W3hIUUN3ME21OU45OTF4IN88US=>	NYPSd3ZHW0GQR1XS
A388	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\2TWM2OD13Nj6wPVg2KM7:TR?=	MnTpV2FPT0WU
C2BBe1	NVXvNG16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrNXoc1UUN3ME21Ok4zPjN2IN88US=>	NYnRSpdlW0GQR1XS
GAMG	NVXBeoJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mly4TWM2OD13Nj61PVU2KM7:TR?=	MmXyV2FPT0WU
MKN28	M1;KeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzDTYE5UUN3ME21Ok45ODF\|IN88US=>	M1flOHNCVkeHUh?=
VA-ES-BJ	NHvqUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTV4Lki3OFUh\|ryP	M{K4dnNCVkeHUh?=
HuCCT1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nTXWlEPTB;NUeuNFQ6OiEQvF2=	MnjsV2FPT0WU
BFTC-905	M1;5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLwVnpFUUN3ME21O{4zQDl6IN88US=>	MXvTRW5ITVJ?
LS-123	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTV5LkW2Olgh\|ryP	NF\IZ\|ZUSU6JRWK=
LB996-RCC	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTV6LkCyPFch\|ryP	NUT4NYNyW0GQR1XS
NCI-H1048	M2rVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXQb4lKSzVyPUW4MlIyQDhizszN	NFe0eFdUSU6JRWK=
COR-L105	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXNSpRGUUN3ME21PE44OzN5IN88US=>	MnHsV2FPT0WU
OVCAR-8	NGnsfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTV7LkG3NVYh\|ryP	NH63XpRUSU6JRWK=
SK-N-FI	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLUTWM2OD13OT6zNlA4KM7:TR?=	M1iwZ3NCVkeHUh?=
MES-SA	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHLSodKUUN3ME21PU41PTB7IN88US=>	NF2yd5pUSU6JRWK=
SCC-9	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnCTWM2OD13OT60O\|U{KM7:TR?=	MYjTRW5ITVJ?
EFO-27	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7KWVhjUUN3ME21PU46PDNizszN	MkHWV2FPT0WU
GT3TKB	NXznfFJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTZyLk[wOFgh\|ryP	MorGV2FPT0WU
HCC38	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlziTWM2OD14MT60N\|c6KM7:TR?=	NYHpNZNFW0GQR1XS
MLMA	M1LBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfFTIJEUUN3ME22NU43OTZ\|IN88US=>	NV;RV2dMW0GQR1XS
D-566MG	NX\V[WFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LZUWlEPTB;NkOuOVIzPCEQvF2=	NYfUcZF4W0GQR1XS
SF295	NITre5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorOTWM2OD14Mz62OlU2KM7:TR?=	MWfTRW5ITVJ?
ES4	NXLFUIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\wOmlEPTB;NkSuOFcyQSEQvF2=	MmPQV2FPT0WU
CAKI-1	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF[2fYdKSzVyPU[0MlU4OjFizszN	M1Ky[nNCVkeHUh?=
OAW-28	NFrpelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELzRZJKSzVyPU[0Mlk3PDdizszN	MVLTRW5ITVJ?
NCI-H460	NWnIbVdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTwTWM2OD14NT6wPFk4KM7:TR?=	NXTLSm9uW0GQR1XS
JAR	NFXxV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTZ3LkW1NVYh\|ryP	NU[1boNKW0GQR1XS
SNU-449	NHz0Z5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\E[lN1UUN3ME22OU44PjF4IN88US=>	Mn7xV2FPT0WU
D-392MG	M1v3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vvRmlEPTB;NkWuPVQ{PCEQvF2=	NIL6NVdUSU6JRWK=
EW-22	NV;oToxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknUTWM2OD14Nj6zPVUh\|ryP	MX3TRW5ITVJ?
GCT	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTZ5LkC0OFMh\|ryP	NVv3PI5wW0GQR1XS
NOS-1	NYnuOVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXkTWM2OD14Nz62PFY4KM7:TR?=	MWTTRW5ITVJ?
RH-1	NUnTXWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjGWZNwUUN3ME22PE42PTV7IN88US=>	M2nWZXNCVkeHUh?=
HuH-7	NEDueVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTZ7LkGwNFIh\|ryP	MkfXV2FPT0WU
NUGC-3	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTdyLkm2OFQh\|ryP	Ml7uV2FPT0WU
IST-SL1	NWLTVYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jnO2lEPTB;N{GuNlMzPCEQvF2=	NH7ZcY1USU6JRWK=
SHP-77	NEO0U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nNSWlEPTB;N{KuNVE6KM7:TR?=	NVz3OJFxW0GQR1XS
SW1116	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PNe2lEPTB;N{KuNVQxPyEQvF2=	M4fy[XNCVkeHUh?=
LK-2	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTd{Lki2NVIh\|ryP	Mn3LV2FPT0WU
U-2-OS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rwb2lEPTB;N{OuNVgzQCEQvF2=	NF7nVWhUSU6JRWK=
KYSE-150	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTd\|Lk[xNVgh\|ryP	NFfJZ\|hUSU6JRWK=
U251	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;5W4NuUUN3ME23N{45OTZ6IN88US=>	NUjsXGhqW0GQR1XS
HT-1080	NYrMTW5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXy1S\|FpUUN3ME23OE4zPTd2IN88US=>	MnzxV2FPT0WU
NCI-H1437	NFTjTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvrTWM2OD15ND62N\|I3KM7:TR?=	M3HMS3NCVkeHUh?=
HPAF-II	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYCxXWxFUUN3ME23OE43PDF3IN88US=>	M17YV3NCVkeHUh?=
Becker	M4nxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f2WmlEPTB;N{WuNVExPSEQvF2=	M1KzNXNCVkeHUh?=
PANC-10-05	M4K1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3OxTGlEPTB;N{WuNlg3PSEQvF2=	MXzTRW5ITVJ?
TYK-nu	M2H5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTd3LkOxNFIh\|ryP	MnzRV2FPT0WU
SKG-IIIa	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;KTWM2OD15NT6zN\|QyKM7:TR?=	M1jydHNCVkeHUh?=
NCI-H1993	NVGwUY82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjpTWM2OD15NT63N\|k4KM7:TR?=	MWjTRW5ITVJ?
S-117	NGG2[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTd3Lke1OUDPxE1?	MXPTRW5ITVJ?
HuO9	NUX4[phvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrNTWM2OD15Nj6wNFQ5KM7:TR?=	M3;DVXNCVkeHUh?=
CAL-51	NETJOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjKdY9CUUN3ME23Ok4yODB4IN88US=>	NFrEVZFUSU6JRWK=
BT-20	MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTd4LkKxOlgh\|ryP	M2TWSHNCVkeHUh?=
LB831-BLC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPRfZB7UUN3ME23Ok4{OjF5IN88US=>	M3GwUXNCVkeHUh?=
LB1047-RCC	NFHHOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPxXoJ1UUN3ME23Ok44PjF7IN88US=>	NGPSRmpUSU6JRWK=
ES8	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LyeGlEPTB;N{iuNFA4OyEQvF2=	M2fBeHNCVkeHUh?=
UMC-11	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnoTWM2OD15OD6wPFg1KM7:TR?=	M{TTdXNCVkeHUh?=
NCI-H226	NU\3NJFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rtNWlEPTB;N{iuNVMyPSEQvF2=	MnPUV2FPT0WU
IGROV-1	NVSzdVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;le2NbUUN3ME23PE42PTVizszN	MmiwV2FPT0WU
BHY	M1TSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i5bWlEPTB;N{muOVk3KM7:TR?=	MULTRW5ITVJ?
MKN45	NI\5SYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PONWlEPTB;OECuN\|E4PCEQvF2=	MV7TRW5ITVJ?
IA-LM	NV:yRmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fwRWlEPTB;OECuN\|UyOSEQvF2=	MnjLV2FPT0WU
WM-115	NFfSXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7GbpJKSzVyPUixMlQyOTRizszN	MU\TRW5ITVJ?
VMRC-RCZ	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmGwTWM2OD16MT60OFI2KM7:TR?=	NYHxUVM2W0GQR1XS
NCI-H2291	M3\E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXrTWM2OD16MT62PFQzKM7:TR?=	MUjTRW5ITVJ?
MCF7	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;T[5Z3UUN3ME24N{4zQDl5IN88US=>	NHnwNYNUSU6JRWK=
639-V	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzrTWM2OD16ND62NVI6KM7:TR?=	NITpeYRUSU6JRWK=
RT4	NWH0WYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn3TWM2OD16NT6yOFA{KM7:TR?=	NWH1bGVNW0GQR1XS
NCI-H2405	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TrSWlEPTB;OEWuNlk6PyEQvF2=	MWPTRW5ITVJ?
CAL-33	NXX0ZWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzP[3FKSzVyPUi1MlY{OTVizszN	NWTYTVdNW0GQR1XS
BT-549	NFfzUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTh3LkmzPFIh\|ryP	M1vQbHNCVkeHUh?=
HT-1197	M{nLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HST2lEPTB;OEiuNVA4PyEQvF2=	NWrlToFLW0GQR1XS
G-361	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD4Oo1HUUN3ME24PE4yPDd2IN88US=>	NHL1NJJUSU6JRWK=
LS-411N	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEexdm9KSzVyPUi5MlM{QDhizszN	NWHSPGNjW0GQR1XS
HT-144	NFfFW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\ofJZKSzVyPUi5MlU6QTJizszN	MmiwV2FPT0WU
DJM-1	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoGxTWM2OD16OT64PFQ2KM7:TR?=	MWXTRW5ITVJ?
CAL-12T	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTlyLke4PVUh\|ryP	MmDTV2FPT0WU
MKN7	NFj4SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTlzLkO1OVEh\|ryP	M3HkRXNCVkeHUh?=
HuP-T3	NIjuWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4K2bWlEPTB;OU[uNVAxPCEQvF2=	NEXW[45USU6JRWK=
SK-MG-1	M4TXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTl4LkGzOFgh\|ryP	MlXPV2FPT0WU
NCI-H2347	NI\MbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvQc4prUUN3ME25PE4yODR{IN88US=>	NX3sZYl4W0GQR1XS
SW872	NInZVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTFyMD60OVYh\|ryP	NIfLPJBUSU6JRWK=
COLO-829	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fDS2lEPTB;MUCwMlU2OyEQvF2=	NX24SWc5W0GQR1XS
MC-IXC	NGLtSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTLZ21mUUN3ME2xNFAvPjF3IN88US=>	NEG4R45USU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671